Based on target prediction programs (miRTarBase, TargetScan, miRanda, and MiRBase) and published papers, we found highly evidenced candidate target genes (hypoxia-inducible factor 1A and Cullin 2 genes for hypoxia and angiogenesis; cyclin-dependent kinase 6
(CDK6), Cyclin D1 (CCND1), Cyclin E1 (CCNE1), and CCND3 genes for cell cycle) of hsa-miR-424-5p.
For example, CDK4/6 inhibitors have promise as therapeutic interventions in the presence of alterations in various members of the CDK4/6 pathway, including cyclin D1 (CCND1), cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4 (CDK4), and cyclin-dependent kinase 6
(CDK6) (16, 17).
It has an essential role in differentiation of neural stems cells and neural progenitor cells (34), and its downregulation promotes growth, invasiveness, and metastasis (35) by targeting laminin, gamma 1 (LAMC1), integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), cyclin-dependent kinase 6
(CDK6), and SRY (sex determining region Y)-box9 (SOX9) (36).